

RISK ASSESSMENT OF NOVEL FOODS

Océane Albert & Irene Nuin Novel Foods Team Nutrition and Food Innovation Unit



PRESENTATION OUTLINE

EFSA NOVEL FOODS FRAMEWORK

- What is a novel food?
- How are novel foods regulated?
- How are novel foods assessed?

NOVEL FOODS IN THE EU

- What are the different categories of novel foods?
- What are the trends in novel foods at the moment?
- Recent examples







WHAT IS A NOVEL FOOD?



Foods or ingredients that have not been used for human consumption to a significant degree in the EU before 15 May 1997

- Phenylcapsaicin
- Non-sticky base for chewing gum
- Ice-structuring protein

New synthetised or isolated compounds







- Krill oil
- Lycopene from Blakeslea trispora
- Yellow mealworms (Tenebrio molitor)

New sources







xylanisolvens

mushrooms

Milk products

UV-treated yeast or

fermented with B.





- Haskap berries
- Cacao pulp
- Coffee leaves

Traditional













NOVEL FOODS REGULATION IN THE EU

Regulation (EC) No 258/97 (past) Application submitted to EU Member State(s) & European Commission Safety Assessment needed? NO YES Initial Assessment by Member State Reasoned objection(s Centralized procedure by Member State(s afety Assessment by EFSA needed? Safety Assessment by NO

Decision on authorization




Regulation (EU) 2015/2283

From January 2018, centralised risk assessment by EFSA



Regulation (EU) 2015/2283 (current)





NOVEL FOOD AUTHORISATION PROCEDURE













Validate the dossier Mandate EFSA to carry out the risk assessment (NF only)

Carry out the risk assessment (NF)


NF: 9 months TF: 4 months

May request additional information to the applicant (NF) or raise duly reasoned safety objections (TF)

Decide on market authorisation Integration to the Union List of authorized novel foods



RISK ASSESSMENT PROCESS



NOVEL FOOD GUIDANCE (2016 & 2021)

- Administrative data
- Introduction
- Identity of the novel food
- Production process
- Compositional data
- Specifications
- History of use of the novel food and its source
- Proposed uses and use levels, anticipated intake
- Absorption, distribution, metabolism, excretion (ADME)
- Nutritional information
- Toxicological information
- Allergenicity
- Conclusions



EFSA Journal

ADOPTED: 21 September 2016 doi: 10.2903/j.efsa.2016.4594

Guidance on the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283

EFSA Panel on Dietetic Products, Nutrition and Allergie Dominique Turck, Jean-Louis Bresson, Barbara Burlingame Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Erns Harry McArdle, Androniki Naska, Monika Neuhäuser-Berthold, (Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Marti Marco Vinceti, Peter Willatts, Karl-Heinz Engel, Rosangela Marche Morten Poulsen, Seppo Salminen, Josef Schlatter, Davide Arcella, 1 Agnès de Sesmaisons-Lecarré, Hans Verhagen and Hendrik

Abstract

Following the adoption of Regulation (EU) 2015/2283 of the European Parl on novel foods, the European Commission requested EFSA to update a technical guidance for the preparation and presentation of applications foods. This guidance presents a common format for the organisation presented in order to assist the applicant in preparing a well-structured appl safety of the novel food. The application should be comprehensive and outlined the data needed for the safety assessments of novel foods. Requ covered in all applications relate to the description of the novel fi compositional data, specification, proposed uses and use levels, and antic food. Further sections on the history of use of the novel food and/o distribution, metabolism, excretion, nutritional information, toxicological inf should be considered by the applicant by default. If not covered in the a justified. The applicant should integrate the data presented in the differen overall considerations on how the information supports the safety of t proposed conditions of use. Where potential health hazards have been discussed in relation to the anticipated intakes of the novel food and the pri On the basis of the information provided, EFSA will assess the safety of proposed conditions of use.

© 2016 European Food Safety Authority. EFSA Journal published by John Wi of European Food Safety Authority.

GUIDANCE



doi:10.2903/j.efsa.2021.655

Guidance on the preparation and submission of an application for authorisation of a novel food in the context of Regulation (EU) 2015/22831 (Revision 1)2

EFSA Panel on Dietstic Products, Nutrition and Allergies (NDA).³
Dominique Turck, Jean-Louis Bresson, Barbara Buringame, Tare Dean,
Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf,
Harry J Nickdle, Andronik Naska, Monika Neuhauser-Berthold, Grazyna Nowicka,
Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Daniel Tomé,
Marco Vincelt, Peter Willatts, Karl-Heinz Engel, Rosangela Marchelli, Annette Poting,
Morten Poulsen, Seppo Salminen, Josef Schlätter, Davide Arcella, Wolfgang Gelbmann,
Agnés de Sesmisions-Learné, Hars Verhapen and Hendrik van Loveren

Endorsement date	21 January 2021
Implementation date	27 March 2021

Abstract

Following the adoption of Regulation (EU) 2015/2283 on novel foods, the European Commission of requested EFSA develop scientific and bethroid guidance for the preparation and submission of applications for authorisation of novel foods. This guidance presents a common format for the organization of the information to be presented by the applicant when preparing a well-strude application to demonstrate the safety of the novel food. It outlines the data needed for the safety of the process composition of data, specification, proposed uses and use levels, and anticipated intake of the distribution, metabolism, exerction, northerola information, toxicological information and allergenicity should be considered by the applicant by default. If not covered in the application, this should be invited. The applicant should integrate the data presented in the different sections to provide the overall considerations on how the information supports the safety of the novel food under the proposed conditions of use. Where potential health hazards have been identified, they should be discussed in relation to the anticipated intake of the novel food and the proposed conditions of use. Where potential health hazards have been identified, they should be discussed in relation to the anticipated intake of the novel food under the rovosed condition of use.

This guidance was originally adopted in 2016. It has been revised to inform applicants of the new provisions introduced by Regulation (EC) No 178/2002, as amended by Regulation (EU) 2019/1381 on the transparency and sustainability of the EU risk assessment in the food chain. This revised quidance

www.efsa.europa.eu/efsaicumal

EFSA Journal 2021;19(3):6555

The guidance was adopted on 21 September 2016 by the former Parel on District products, Nutrition and Allerges. This revision only aims to efform applicant of the easy previous districtance by the General Facel Law (Regulation (Ed. No. 17/10/2016, 16) to 17/10/2016, and the second product of the Commission of the Com

³ As of 1 July 2018, it has been renamed 'Panel on Nutrition, Novel Foods and Food Allergens (NDA)

FUNDAMENTAL PRINCIPLES



The novel food shall be safe under the proposed conditions of use



The novel food cannot be nutritionally disadvantageous



The efficacy of the novel food is not assessed







NOVEL FOOD CATEGORIES | REGULATION (EU) 2015/2283

New production process

New or modified molecular structure



From microorganisms, fungi or algae



From plants or their parts



Vitamins and minerals from new process / nanomaterials



Of mineral origin



From animals or their parts



Cell or tissue cultures derived from the living



Engineered nanomaterials




Exclusive use in food supplements prior to May 1997





NOVEL FOOD APPLICATIONS UNDER RISK ASSESSMENT





TRENDS IN THE NOVEL FOODS AREA





NOVEL PROTEINS AND THEIR SOURCES

NOVEL PROTEINS AND THEIR SOURCES
























INSECTS & PRODUCTS THEREOF




















Acheta domesticus adults (house cricket)
























PLANTS & PRODUCTS THEREOF: PROTEIN CONTENT



Powder: 33-43 % Isolate: ≥ 90 %

& protein isolate



Mung bean protein powder

85 %



Alfalfa protein concentrate

45 - 60 %



Chia seeds

Seeds 15-26 % Powder ≥ 40 %



Water lentil powder

35-55 %



ALGAE & PRODUCTS THEREOF



Macroalgae


• Laminaria digitata

Microalgae

- Galdieria sulphuraria
- Tetraselmis chuii
- Phaeodactylum tricornutum
- Schizochytrium sp.




CELL-CULTURED DERIVED FOODS




Simplified view of the production process






NOVEL CARBOHYDRATES

HUMAN IDENTICAL MILK OLIGOSACCHARIDES (HIMOs)







SUGAR REPLACERS



All mono-, di- and oligo-saccharides with new or intentionally modified molecular structure, where that structure was not used as, or in, a food within the Union before 15 May 1997


Starch hydrolysates Other sugars Isomaltulose

Isomalto-oligosaccharide

Galacto-oligosaccharides

Allulose

Cellobiose







PLANT EXTRACTS



PLANT EXTRACTS: THE EXAMPLE OF CBD



Cannabidiol (CBD) extracted from *Cannabis sativa L.* or chemically synthetised



Authorized in the EU as orphan drug for the treatment of rare epilepsies (Epidyolex®)



European Court of Justice (Nov. 2020) decided that CBD was not a narcotic and should be considered as novel for uses as food ingredients and supplements



20 dossiers under evaluation at EFSA, >150 dossiers at the European Commission level



All dossiers under assessment at EFSA were requested additional data to fill in the data gaps identified in the Statement

STATEMENT



ADOPTED: 26 April 2022 doi: 10.2903/j.efsa.2022.7322

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA),
Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw,
Karen Ildico Hirsch-Ernst, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies,
Sophia Tsabouri, Marco Vinceti, Francesco Cubadda, Thomas Frenzel, Marina Heinonen,
Rosangela Marchelli, Monika Neuhäuser-Berthold, Morten Poulsen, Miguel Prieto Maradona,
Josef Rudolf Schlatter, Viviana Trezza, Henk van Loveren, Océane Albert, Céline Dumas,
Andrea Germini, Wolfgang Gelbmann, Georges Kass, Eirini Kouloura,
Estefania Noriega Fernandez, Annamaria Rossi and Helle Katrine Knutsen







STAY CONNECTED

SUBSCRIBE TO

efsa.europa.eu/en/news/newsletters efsa.europa.eu/en/rss Careers.efsa.europa.eu – job alerts



FOLLOW US ON TWITTER

@efsa_eu

@methods_efsa

@plants_efsa





@one_healthenv_eu



LISTEN TO OUR PODCAST

Science on the Menu –Spotify, Apple Podcast and YouTube



FOLLOW US ON LINKEDIN

Linkedin.com/company/efsa



CONTACT US

efsa.europe.eu/en/contact/askefsa



